Taichung, Taiwan
NCT Number: NCT00647920
Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
A Randomized, Double-Blind, Placebo-Controlled, Study of the Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with Methotrexate
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits 6 swollen joints and 9 tender joints.
Exclusion criteria
- A history of, or current, acute inflammatory joint disease of different origin than RA (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus or any arthritide with onset prior to age 16 years).
Treatment and study plan
Adalimumab
Biological40 mg adalimumab sc, every other week
Other names: ABT-D2E7, Humira
Placebo
Biologicalplacebo sc, every other week
Primary outcomes
-
ACR20
Time frame: Week 12
Secondary outcomes
-
ACR50
Time frame: Week 12
-
ACR70
Time frame: Week 12
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Abbott
Industry
Registry information
Official study title
Study of the Human Anti-TNF-Antibody Adalimumab
Important dates
- Study start
- 2003
- Primary completion
- 2005
- First posted
- Apr 1, 2008
- Registry last updated
- Apr 1, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Health Literacy, Rational Drug Use, and Cyberchondria in Rheumatic Diseases
NCT06993935
Arthritis, Arthritis, Rheumatoid
Yozgat, Turkey (Türkiye)
View Trial DetailsUmbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis
NCT07715045
Arthritis, Arthritis, Rheumatoid
Palembang, South Sumatera, Indonesia
View Trial DetailsStudy of Families With Twins or Siblings Discordant for Rheumatic Disorders
NCT00055055
Arthritis, Arthritis, Rheumatoid
Bethesda, Maryland, United States
View Trial DetailsA Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT05638854
Arthritis, Arthritis, Rheumatoid
Melbourne, Australia
View Trial Details